Journal
STEM CELLS TRANSLATIONAL MEDICINE
Volume 6, Issue 11, Pages 1956-1962Publisher
WILEY
DOI: 10.1002/sctm.17-0144
Keywords
Human pluripotent stem cells; Human embryonic stem cell (hESC); Induced pluripotent stem cell (iPSC); Stem cell banking; Quality assurance; Quality control; Data standardization; Informed consents
Categories
Funding
- CiRM
- KNIH [2016-NG61002-00]
- Grants-in-Aid for Scientific Research [17H06396] Funding Source: KAKEN
Ask authors/readers for more resources
This article summarizes the recent activity of the International Stem Cell Banking Initiative (ISCBI) held at the California Institute for Regenerative Medicine (CIRM) in California (June 26, 2016) and the Korean National Institutes for Health in Korea (October 19-20, 2016). Through the workshops, ISCBI is endeavoring to support a new paradigm for human medicine using pluripotent stem cells (hPSC) for cell therapies. Priority considerations for ISCBI include ensuring the safety and efficacy of a final cell therapy product and quality assured source materials, such as stem cells and primary donor cells. To these ends, ISCBI aims to promote global harmonization on quality and safety control of stem cells for research and the development of starting materials for cell therapies, with regular workshops involving hPSC banking centers, biologists, and regulatory bodies. Here, we provide a brief overview of two such recent activities, with summaries of key issues raised.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available